



CME DATA SERVICES

2025 Fee & Policy Adjustments Futures and Options

Pursuant to the notice requirements in your market data agreement, this communication provides formal notification that CME will introduce the changes set out in this notice to your market data agreement (as applicable), market data fees and policies in 2025. Please refer to [Market Data Policy Education Center](#) for:

- market data policies;
- a list of all CME 2025 market data fees;
- a copy of updated Information License Agreement and Schedules.

For customers with an Information License Agreement (“ILA”), your individual ILA will be updated to reflect the changes outlined in this notice as applicable, to include the addition of corresponding licenses, if any. Your updated ILA will be available for download from the Data Services Portal on or before **December 31, 2024**, along with the ability to report if applicable. Also, unless otherwise stated, all capitalized terms in this Notice as relevant to the ILA have the same meaning as defined in the ILA.

CME hereby gives notice:

1. Termination of End of Day Information licenses

End of Day Information packages will no longer be offered and as a result:

Effective Date: **April 1, 2025**

- (i) all End of Day Information licenses shall terminate; and
- (ii) all references to End of Day Information are removed from your relevant data license agreement.

1a. Customers with an ILA

The Information previously licensed via End of Day Information packages is still available under corresponding Real-Time Information or Delayed Information packages and that means:

(a) if you are already licensed for a corresponding Real-Time Information or Delayed package, the Information licensed under the terminating End of Day package is available to you under that corresponding data package. There may be some adjustments to reporting obligations and/or fees, see the reference table linked to below; and

(b) for Licensees who do not already possess a corresponding Real-Time Information or a corresponding Delayed Information package license, a substitute corresponding license will be added to your ILA, please refer to the [Reference Table](#) for details on that corresponding license.

1b. Customers not licensed via an ILA

If you are licensed to receive End of Day Information via a CME data license agreement that is not an ILA, please contact your account manager to discuss your license profile.

1c. The following are unaffected by this notice:

References to Delayed End of Day Index and End of Day Index and associated licenses in ILA Schedules 2b, 5 and 7 are unaffected by this notice.

2. Non-Display Use of Information

Non-Display Use licensing is moving, from multiple, to one license type. To facilitate the transition to one license type, both Non-Display Use of Delayed Information and Non-Display Use of End of Day Information will be reportable from **January 1, 2025** through **March 31, 2025**. They will both terminate effective from **April 1, 2025**. From that date, fees will be based on the total number of Applications reported. As a result:

Effective Date: **January 1, 2025**

(i) All Applications accessing Information for Non-Display Use must be reported on an As Needed basis in the Data Services Portal.

Effective Date: **April 1, 2025**

(i) the definition of “Non-Display Use” will be updated.

(ii) all Delayed licenses for Non-Display Use of Information shall terminate.

(iii) Fees will be based on the total number of Applications reported on an As Needed basis.

Please Note: End of Day Non-Display Use licensing is terminated as set out in section 1. above.

2a. Customers with an ILA

If you have a Non-Display Delayed license under an ILA, your Non-Display license will be updated to a single Non-Display license.

2b. Customers not licensed via an ILA

If you are licensed to receive Non-Display Information via a CME data license agreement that is not an ILA, please contact your account manager to discuss your license profile.

In addition, for those customers not licensed via an ILA, the updated definition of “Non-Display Use” is as set in the ILA Schedule 2, please refer to [Market Data Policy Education Center](#).

3. Quote

Effective Date: **January 1, 2025**

Quote Information packages will no longer be offered to new customers.

3a. Customers with an ILA

For customers not currently licensed to receive a Quote Information package, references to Quote will be deleted from your ILA.

3b. Customers not licensed via an ILA

If you are licensed to Quote via a data license agreement that is not an ILA, please contact your account manager to discuss your license profile.

4. Licensee Website Fee Waiver Termination

Effective Date: **April 1, 2025**

(i) all references to Delayed No Charge Website packages are removed from your relevant data license agreement;

(ii) all Licensee Websites will be fee liable at the prevailing Website Fee.

4a. Customers with an ILA

Schedule 5, Section 2.3 will be deleted from your ILA.

4b. Customers not licensed via an ILA

If you are licensed to distribute Information on Websites via a data license agreement that is not an ILA, please contact your account manager to discuss your license profile.

5. Fee Updates

Effective Date: **January 1, 2025**

Market data Fees for all CME, CBOT, NYMEX and COMEX Information will be revised as of **January 1, 2025**. Revised fees are included in the Market Data Fee List for 2025, available at: [Market Data Policy Education Center](#)

Fees for CME, CBOT, NYMEX and COMEX Information accessed via the DataMine platform are published in the DataMine product catalog: datamine.cmegroup.com.

Please Note: The annual subscription fees become effective at your next subscription renewal.

If you have any questions related to any of the changes set out in this notice, please contact your account manager or marketdata@cmegroup.com.



[Privacy Notice](#) | [Terms of Use](#) | [Cookie Notice](#) | [Disclaimer](#)

Where risk meets opportunity. As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) is where the world comes to manage risk. CME Group enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data. CME Group exchanges offer the widest range of global benchmark products across all major asset classes including interest rates, equity indexes, FX, energy, agricultural products and metals.

Neither futures trading nor swaps trading are suitable for all investors, and each involves the risk of loss. Swaps trading should only be undertaken by investors who are Eligible Contract Participants (ECPs) within the meaning of Section 1a(18) of the Commodity Exchange Act. Futures and swaps each are leveraged investments and, because only a percentage of a contract's value is required to trade, it is possible to lose more than the amount of money deposited for either a futures or swaps position. Therefore, traders should only use funds that they can afford to lose without affecting their lifestyles and only a portion of those funds should be devoted to any one trade because traders cannot expect to profit on every trade.

CME Group®, the CME Group Globe logo, and CME® are trademarks of Chicago Mercantile Exchange, Inc.

Copyright © 2025 CME Group. All rights reserved.

Mailing Address: 20 South Wacker Drive, Chicago, Illinois 60606

You have received this email because you subscribed to CME Globex.

[Unsubscribe](#)

[Update my subscription settings](#)